Systemic sclerosis sine scleroderma: A multicenter study of 1417 subjects

Journal of Rheumatology

Volumn 41, Issue 11, 2014, Pages 2179-2185

  Diab, Sehriban ^a   Dostrovsky, Nathaniel ^a   Hudson, Marie ^b,c   Tatibouet, Solène ^c   Fritzler, Marvin J ^d   Baron, Murray ^b,c   Khalidi, Nader ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

Diffuse systemic sclerosis; Limited systemic sclerosis; Scleroderma sine scleroderma; Systemic sclerosis

Indexed keywords

CENTROMERE ANTIBODY; ENZYME ANTIBODY; LA ANTIBODY; RNA POLYMERASE III ANTIBODY; TOPOISOMERASE I ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY DETECTION; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; DIFFUSE SCLERODERMA; DISEASE REGISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; INTERSTITIAL LUNG DISEASE; LOCALIZED SCLERODERMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROLOGY; SKIN MANIFESTATION; SYSTEMIC SCLEROSIS; AGE DISTRIBUTION; CANADA; CLINICAL TRIAL; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; REGISTER; RISK ASSESSMENT; SCLERODERMA, DIFFUSE; SCLERODERMA, LIMITED; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SEX RATIO; SURVIVAL;

ADULT; AGE DISTRIBUTION; CANADA; COHORT STUDIES; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; REGISTRIES; RISK ASSESSMENT; SCLERODERMA, DIFFUSE; SCLERODERMA, LIMITED; SCLERODERMA, SYSTEMIC; SEROLOGIC TESTS; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SURVIVAL ANALYSIS;

EID: 84923247155     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.140236     Document Type: Article

References (24)

1. Abrams HL, Carnes WH, Eaton J. Alimentary tract in disseminated scleroderma with emphasis on small bowel. AMA Arch Intern Med 1954; 94:61-81.
2. Poormoghim H, Lucas M, Fertig N., Medsger TA Jr. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum 2000; 43:444-51.
3. Hunzelmann N, Genth E, Krieg T., Lehmacher W, Melchers I, Meurer M., et al. The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology 2008; 47:1185-92.
4. Simeon-Aznar CP, Fonollosa-Pla V, Tolosa-Vilella C, Espinosa-Garriga G, Ramos-Casals M, Campillo-Grau M, et al. Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status. Semin Arthritis Rheum 2011; 41:789-800.
5. Marangoni RG, Rocha LF, Del Rio AP, Yoshinari NH, Marques-Neto JF, Sampaio-Barros PD. Systemic sclerosis sine scleroderma: distinct features in a large Brazilian cohort. Rheumatology 2013; 52:1520-4.
6. Toya SP, Tzelepis GE. The many faces of scleroderma sine scleroderma: a literature review focusing on cardiopulmonary complications. Rheumatol Int 2009; 29:861-8.
7. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23:581-90.
8. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2013; 72:1747-55.
9. Alhajeri H, Hudson M, Fritzler M., Pope J, Baron M. Evaluation of the new American College of Rheumatology /European League Against Rheumatism criteria for the classification of systemic sclerosis in the Canadian Scleroderma Research Group cohort [abstract]. Arthritis Rheum 2013; 65 Suppl 10:S772.
10. Clements P, Lachenbruch P, S iebold J, White B, Weiner S., Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22:1281-5.
11. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28:1573-6.
12. Steele R, Hudson M, Lo E., Baron M. A clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. Arthritis Care Res 2012; 64:519-24.
13. Hsu VM, Moreyra AE, Wilson A.C., Shinnar M., Shindler DM, Wilson JE, et al. Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. J Rheumatol 2008; 35:458-65.
14. Fries JF, Spitz P, Kraines R.G., Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23:137-45.
15. Steen VD, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997; 40:1984-91.
16. Medsger TA Jr, Bombardieri S, Czirjak L., Scorza R, Delia Rossa A, Bencivelli W. Assessment of disease severity and prognosis. Clin Exp Rheumatol 2003; 21 Suppl 29:S42-6.
17. Hudson M, Mahler M, Pope J., You D, Tatibouet S, Steele R., et al. Clinical correlates of CENP-A and CENP-B antibodies in a large cohort of patients with systemic sclerosis. J Rheumatol 2012; 39:787-94.
18. Santiago M, Baron M, Hudson M., Burlingame RW, Fritzler MJ. Antibodies to RNA polymerase III in systemic sclerosis detected by ELISA. J Rheumatol 2007; 34:1528-34.
19. Mahler M, Raijmakers R, Dahnrich C., Bluthner M, Fritzler MJ. Clinical evaluation of autoantibodies to a novel PM/Scl peptide antigen. Arthritis Res Ther 2005; 7:R704-13.
20. Hudson M, Pope J, Mahler M., Tatibouet S, Steele R, Baron M., et al. Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis. Arthritis Res Ther 2012; 14:R50.
21. Mehra S, Walker J, Patterson K., Fritzler MJ. Autoantibodies in systemic sclerosis. Autoimmun Rev 2013; 12:340-54.
22. Mierau R, Moinzadeh P, Riemekasten G., Melchers I, Meurer M, Reichenberger F., et al. Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features. Arthritis Res Ther 2011; 13:R172.
23. D'Aoust J., Hudson M, Tatibouet S., Wick J, Mahler M, Baron M., et al. Clinical and serological correlates of anti-PM/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients. Arthritis Rheumatol 2014; 66:1608-15.
24. Mahler M, Miller FW, Fritzler MJ. Idiopathic inflammatory myopathies and the anti-synthetase syndrome: A comprehensive review. Autoimmun Rev 2014; 13:367-71.